Lantheus (NASDAQ:LNTH) Issues Earnings Results, Misses Estimates By $0.07 EPS

Lantheus (NASDAQ:LNTH) released its quarterly earnings results on Wednesday. The medical equipment provider reported $1.61 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.68 by ($0.07), Zacks reports. The firm had revenue of $394.10 million for the quarter, compared to analysts’ expectations of $382.12 million. Lantheus had a return on equity of 51.41% and a net margin of 29.80%. The company’s quarterly revenue was up 22.5% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.40 EPS. Lantheus updated its FY24 guidance to $6.60-6.70 EPS and its FY 2024 guidance to 6.600-6.700 EPS.

Lantheus Price Performance

Shares of Lantheus stock traded down $3.19 during trading on Friday, reaching $95.43. The company’s stock had a trading volume of 279,803 shares, compared to its average volume of 1,078,775. The company has a quick ratio of 4.55, a current ratio of 4.84 and a debt-to-equity ratio of 0.59. Lantheus has a 12-month low of $50.20 and a 12-month high of $126.89. The company has a market capitalization of $6.61 billion, a P/E ratio of 15.06 and a beta of 0.51. The business has a 50 day moving average price of $91.79 and a 200-day moving average price of $72.83.

Insider Activity at Lantheus

In related news, Director Heinz Christoph Maeusli sold 18,373 shares of Lantheus stock in a transaction that occurred on Tuesday, May 28th. The stock was sold at an average price of $79.19, for a total value of $1,454,957.87. Following the sale, the director now directly owns 23,340 shares in the company, valued at $1,848,294.60. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. In related news, Director Heinz Christoph Maeusli sold 18,373 shares of Lantheus stock in a transaction on Tuesday, May 28th. The stock was sold at an average price of $79.19, for a total transaction of $1,454,957.87. Following the completion of the transaction, the director now directly owns 23,340 shares of the company’s stock, valued at $1,848,294.60. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, insider Daniel Niedzwiecki sold 12,873 shares of the business’s stock in a transaction dated Thursday, May 30th. The stock was sold at an average price of $79.86, for a total transaction of $1,028,037.78. Following the completion of the sale, the insider now owns 80,244 shares in the company, valued at $6,408,285.84. The disclosure for this sale can be found here. Insiders have sold a total of 44,799 shares of company stock worth $3,769,262 over the last three months. 1.50% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

LNTH has been the topic of a number of research reports. JMP Securities dropped their price target on Lantheus from $130.00 to $125.00 and set a “market outperform” rating on the stock in a research note on Thursday. Truist Financial lowered their target price on Lantheus from $141.00 to $135.00 and set a “buy” rating on the stock in a research note on Thursday. StockNews.com downgraded Lantheus from a “buy” rating to a “hold” rating in a research note on Friday, May 3rd. B. Riley lifted their target price on Lantheus from $105.00 to $146.00 and gave the company a “buy” rating in a research note on Thursday, July 25th. Finally, Mizuho lifted their target price on Lantheus from $90.00 to $100.00 and gave the company a “buy” rating in a research note on Friday, May 3rd. Two investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat.com, Lantheus currently has a consensus rating of “Moderate Buy” and an average price target of $119.00.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.